(1S,5R)-4-[(1E)-2-(3,4-Dihydroxy-5-methoxyphenyl)ethenyl]-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one
Atherosclerosis
Shin Poong Pharmaceutical Co. Ltd.Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
19 Active assets in the Atherosclerosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Acetylsalicylic Acid Rajaie Cardiovascular Medical and Research Center | Phase 4 | BBB |
SIMVASTATIN Northern California Institute of Research and Education | Phase 4 | BBB |
ADVICOR COMPONENT NIACIN University of Washington | Phase 4 | BB |
Lipitor Erasmus Medical Center | Phase 4 | BB |
Ezetimibe paresh Dandona | Phase 4 | BB |
View all 49 →
Same molecule, other indications
(1S,5R)-4-[(1E)-2-(3,4-Dihydroxy-5-methoxyphenyl)ethenyl]-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →